Which has better earnings & valuation, OBI or ABC?

Abcam has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ondine Biomedical C$2.65M 2,650.77 -C$424.66K -C$7.00 N/A Abcam £350.40M 0.00 N/A £0.06 N/A

Is OBI or ABC more profitable?

Abcam has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,117.06%. Abcam's return on equity of 0.00% beat Ondine Biomedical's return on equity. Company Net Margins Return on Equity Return on Assets Ondine Biomedical -1,117.06% -1,411.54% -159.71% Abcam N/A N/A N/A

Do analysts prefer OBI or GNS?

Genus has a consensus price target of GBX 3,216.67, suggesting a potential upside of 51.73%. Given Genus' stronger consensus rating and higher probable upside, analysts plainly believe Genus is more favorable than Ondine Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ondine Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Genus 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher valuation & earnings, OBI or GNS?

Genus has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ondine Biomedical C$2.65M 2,650.77 -C$424.66K -C$7.00 N/A Genus £672M 2.10 £7.87M £71.00 29.86

Is OBI or GNS more profitable?

Genus has a net margin of 7.07% compared to Ondine Biomedical's net margin of -1,117.06%. Genus' return on equity of 9.70% beat Ondine Biomedical's return on equity. Company Net Margins Return on Equity Return on Assets Ondine Biomedical -1,117.06% -1,411.54% -159.71% Genus 7.07% 9.70% 3.31%

Do analysts prefer OBI or OXB?

Oxford Biomedica has a consensus target price of GBX 633.38, indicating a potential upside of 5.00%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, analysts plainly believe Oxford Biomedica is more favorable than Ondine Biomedical. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ondine Biomedical 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Oxford Biomedica 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has preferable valuation and earnings, OBI or ERGO?

Ergomed has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ondine Biomedical C$2.65M 2,650.77 -C$424.66K -C$7.00 N/A Ergomed £152.09M 0.00 £15M £0.29 N/A

Is OBI or ERGO more profitable?

Ergomed has a net margin of 9.87% compared to Ondine Biomedical's net margin of -1,117.06%. Ergomed's return on equity of 18.08% beat Ondine Biomedical's return on equity. Company Net Margins Return on Equity Return on Assets Ondine Biomedical -1,117.06% -1,411.54% -159.71% Ergomed 9.87% 18.08% 10.16%

Ondine Biomedical (OBI) Competitors

C$13.50 -0.50 (-3.57%)

As of 03:26 PM Eastern

Compare

OBI vs. ABC, GNS, ONT, OXB, and ERGO

Should you buy Ondine Biomedical stock or one of its competitors? MarketBeat compares Ondine Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Ondine Biomedical include Abcam (ABC), Genus (GNS), Oxford Nanopore Technologies (ONT), Oxford Biomedica (OXB), and Ergomed (ERGO). These companies are all part of the "biotechnology" industry.

How does Ondine Biomedical compare to Abcam?

Ondine Biomedical (LON:OBI) and Abcam (LON:ABC) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.

30.0% of Ondine Biomedical shares are owned by institutional investors. 37.4% of Ondine Biomedical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Abcam has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Abcam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.65M	2,650.77	-C$424.66K	-C$7.00	N/A
Abcam	£350.40M	0.00	N/A	£0.06	N/A

In the previous week, Ondine Biomedical's average media sentiment score of 0.00 equaled Abcam'saverage media sentiment score.

Company	Overall Sentiment
Ondine Biomedical	Neutral
Abcam	Neutral

Abcam has a net margin of 0.00% compared to Ondine Biomedical's net margin of -1,117.06%. Abcam's return on equity of 0.00% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%
Abcam	N/A	N/A	N/A

Summary

Abcam beats Ondine Biomedical on 6 of the 8 factors compared between the two stocks.

How does Ondine Biomedical compare to Genus?

Ondine Biomedical (LON:OBI) and Genus (LON:GNS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends.

Ondine Biomedical has a beta of 0.321, meaning that its share price is 68% less volatile than the broader market. Comparatively, Genus has a beta of 0.901, meaning that its share price is 10% less volatile than the broader market.

Genus has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Genus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.65M	2,650.77	-C$424.66K	-C$7.00	N/A
Genus	£672M	2.10	£7.87M	£71.00	29.86

30.0% of Ondine Biomedical shares are held by institutional investors. Comparatively, 52.2% of Genus shares are held by institutional investors. 37.4% of Ondine Biomedical shares are held by insiders. Comparatively, 0.7% of Genus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Genus' average media sentiment score of 0.37 beat Ondine Biomedical's score of 0.00 indicating that Genus is being referred to more favorably in the news media.

Company	Overall Sentiment
Ondine Biomedical	Neutral
Genus	Neutral

Genus has a net margin of 7.07% compared to Ondine Biomedical's net margin of -1,117.06%. Genus' return on equity of 9.70% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%
Genus	7.07%	9.70%	3.31%

Genus has a consensus price target of GBX 3,216.67, suggesting a potential upside of 51.73%. Given Genus' stronger consensus rating and higher probable upside, analysts plainly believe Genus is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Genus	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Genus beats Ondine Biomedical on 13 of the 15 factors compared between the two stocks.

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Oxford Nanopore Technologies (LON:ONT) and Ondine Biomedical (LON:OBI) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, profitability, valuation and earnings.

Oxford Nanopore Technologies currently has a consensus target price of GBX 212.60, suggesting a potential upside of 92.05%. Given Oxford Nanopore Technologies' stronger consensus rating and higher possible upside, equities analysts plainly believe Oxford Nanopore Technologies is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oxford Nanopore Technologies	0 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.80
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Oxford Nanopore Technologies had 3 more articles in the media than Ondine Biomedical. MarketBeat recorded 3 mentions for Oxford Nanopore Technologies and 0 mentions for Ondine Biomedical. Oxford Nanopore Technologies' average media sentiment score of 0.58 beat Ondine Biomedical's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Oxford Nanopore Technologies	Positive
Ondine Biomedical	Neutral

Ondine Biomedical has lower revenue, but higher earnings than Oxford Nanopore Technologies. Oxford Nanopore Technologies is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Oxford Nanopore Technologies	£223.90M	4.82	-£175.21M	-£15.10	N/A
Ondine Biomedical	C$2.65M	2,650.77	-C$424.66K	-C$7.00	N/A

Oxford Nanopore Technologies has a net margin of -64.85% compared to Ondine Biomedical's net margin of -1,117.06%. Oxford Nanopore Technologies' return on equity of -29.43% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Oxford Nanopore Technologies	-64.85%	-29.43%	-14.42%
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%

16.4% of Oxford Nanopore Technologies shares are held by institutional investors. Comparatively, 30.0% of Ondine Biomedical shares are held by institutional investors. 2.5% of Oxford Nanopore Technologies shares are held by company insiders. Comparatively, 37.4% of Ondine Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Oxford Nanopore Technologies has a beta of 0.92, meaning that its stock price is 8% less volatile than the broader market. Comparatively, Ondine Biomedical has a beta of 0.321, meaning that its stock price is 68% less volatile than the broader market.

Summary

Oxford Nanopore Technologies beats Ondine Biomedical on 10 of the 16 factors compared between the two stocks.

How does Ondine Biomedical compare to Oxford Biomedica?

Ondine Biomedical (LON:OBI) and Oxford Biomedica (LON:OXB) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

30.0% of Ondine Biomedical shares are owned by institutional investors. Comparatively, 32.4% of Oxford Biomedica shares are owned by institutional investors. 37.4% of Ondine Biomedical shares are owned by insiders. Comparatively, 34.8% of Oxford Biomedica shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Ondine Biomedical has a beta of 0.321, suggesting that its share price is 68% less volatile than the broader market. Comparatively, Oxford Biomedica has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market.

Oxford Biomedica has a consensus target price of GBX 633.38, indicating a potential upside of 5.00%. Given Oxford Biomedica's stronger consensus rating and higher possible upside, analysts plainly believe Oxford Biomedica is more favorable than Ondine Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ondine Biomedical	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Oxford Biomedica	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

In the previous week, Ondine Biomedical's average media sentiment score of 0.00 equaled Oxford Biomedica'saverage media sentiment score.

Company	Overall Sentiment
Ondine Biomedical	Neutral
Oxford Biomedica	Neutral

Oxford Biomedica has a net margin of -17.85% compared to Ondine Biomedical's net margin of -1,117.06%. Oxford Biomedica's return on equity of -48.56% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%
Oxford Biomedica	-17.85%	-48.56%	-12.67%

Ondine Biomedical has higher earnings, but lower revenue than Oxford Biomedica. Oxford Biomedica is trading at a lower price-to-earnings ratio than Ondine Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.65M	2,650.77	-C$424.66K	-C$7.00	N/A
Oxford Biomedica	£168.74M	4.33	-£143.51M	-£26.92	N/A

Summary

Oxford Biomedica beats Ondine Biomedical on 9 of the 14 factors compared between the two stocks.

How does Ondine Biomedical compare to Ergomed?

Ondine Biomedical (LON:OBI) and Ergomed (LON:ERGO) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, valuation, earnings, profitability, dividends, risk, analyst recommendations and institutional ownership.

Ondine Biomedical has a beta of 0.321, meaning that its share price is 68% less volatile than the broader market. Comparatively, Ergomed has a beta of 0.79, meaning that its share price is 21% less volatile than the broader market.

Ergomed has higher revenue and earnings than Ondine Biomedical. Ondine Biomedical is trading at a lower price-to-earnings ratio than Ergomed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ondine Biomedical	C$2.65M	2,650.77	-C$424.66K	-C$7.00	N/A
Ergomed	£152.09M	0.00	£15M	£0.29	N/A

In the previous week, Ondine Biomedical's average media sentiment score of 0.00 equaled Ergomed'saverage media sentiment score.

Company	Overall Sentiment
Ondine Biomedical	Neutral
Ergomed	Neutral

Ergomed has a net margin of 9.87% compared to Ondine Biomedical's net margin of -1,117.06%. Ergomed's return on equity of 18.08% beat Ondine Biomedical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ondine Biomedical	-1,117.06%	-1,411.54%	-159.71%
Ergomed	9.87%	18.08%	10.16%

30.0% of Ondine Biomedical shares are owned by institutional investors. Comparatively, 71.1% of Ergomed shares are owned by institutional investors. 37.4% of Ondine Biomedical shares are owned by company insiders. Comparatively, 18.2% of Ergomed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Ergomed beats Ondine Biomedical on 9 of the 10 factors compared between the two stocks.

Get Ondine Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OBI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OBI vs. The Competition

Export

Metric	Ondine Biomedical	Biotechnology Industry	Medical Sector	LON Exchange
Market Cap	C$7.01B	C$515.16M	C$6.81B	C$2.79B
Dividend Yield	N/A	3.90%	2.67%	6.16%
P/E Ratio	-1.93	3.15	27.00	368.25
Price / Sales	2,650.77	6,249.84	517.32	84,392.87
Price / Cash	1.99	13.13	26.68	27.89
Price / Book	1,563.47	87.68	10.67	7.59
Net Income	-C$424.66K	-C$96.07M	C$3.60B	C$5.89B
7 Day Performance	-1.82%	-0.59%	-0.37%	0.05%
1 Month Performance	-9.64%	1.23%	1.80%	-0.66%
1 Year Performance	1.89%	60.49%	25.50%	62.48%

Ondine Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OBI Ondine Biomedical	N/A	C$13.50 -3.6%	N/A	+10.2%	C$7.01B	C$2.65M	N/A	N/A	Gap Up
ABC Abcam	N/A	N/A	N/A	N/A	£2.81B	£350.40M	20,433.33	1,650	Gap Up High Trading Volume
GNS Genus	3.5001 of 5 stars	GBX 2,020 -2.5%	GBX 3,216.67 +59.2%	-10.5%	£1.38B	£672M	28.45	480
ONT Oxford Nanopore Technologies	3.4254 of 5 stars	GBX 120.30 +1.2%	GBX 218.60 +81.7%	-26.1%	£1.16B	£223.90M	N/A	1,281	Analyst Downgrade
OXB Oxford Biomedica	1.05 of 5 stars	GBX 611 +0.2%	GBX 600.04 -1.8%	+64.3%	£738.33M	£168.74M	N/A	891	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (LON:OBI) was last updated on 7/21/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Ondine Biomedical (OBI) Competitors

OBI vs. ABC, GNS, ONT, OXB, and ERGO

How does Ondine Biomedical compare to Abcam?

Summary

How does Ondine Biomedical compare to Genus?

Summary

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Summary

How does Ondine Biomedical compare to Oxford Biomedica?

Summary

How does Ondine Biomedical compare to Ergomed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBI vs. The Competition

Ondine Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Ondine Biomedical (OBI) Competitors

OBI vs. ABC, GNS, ONT, OXB, and ERGO

How does Ondine Biomedical compare to Abcam?

Do institutionals and insiders have more ownership in OBI or ABC?

Which has better earnings & valuation, OBI or ABC?

Does the media refer more to OBI or ABC?

Is OBI or ABC more profitable?

Summary

How does Ondine Biomedical compare to Genus?

Which has more risk and volatility, OBI or GNS?

Which has higher valuation & earnings, OBI or GNS?

Do institutionals and insiders hold more shares of OBI or GNS?

Does the media prefer OBI or GNS?

Is OBI or GNS more profitable?

Do analysts prefer OBI or GNS?

Summary

How does Ondine Biomedical compare to Oxford Nanopore Technologies?

Do analysts prefer ONT or OBI?

Does the media prefer ONT or OBI?

Which has preferable earnings and valuation, ONT or OBI?

Is ONT or OBI more profitable?

Do insiders and institutionals hold more shares of ONT or OBI?

Which has more volatility and risk, ONT or OBI?

Summary

How does Ondine Biomedical compare to Oxford Biomedica?

Do insiders & institutionals have more ownership in OBI or OXB?

Which has more volatility & risk, OBI or OXB?

Do analysts prefer OBI or OXB?

Does the media refer more to OBI or OXB?

Is OBI or OXB more profitable?

Which has preferable valuation and earnings, OBI or OXB?

Summary

How does Ondine Biomedical compare to Ergomed?

Which has more risk and volatility, OBI or ERGO?

Which has preferable valuation and earnings, OBI or ERGO?

Does the media refer more to OBI or ERGO?

Is OBI or ERGO more profitable?

Do insiders and institutionals believe in OBI or ERGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OBI vs. The Competition

Ondine Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools